Table 1.
Combination of Anti-Streptolysin O (ASO) ≥ 200 IU and Anti DNAse B (ADB) ≥ 480 IU in Patients with Narcolepsy and Age-Matched Controls
| Interval from disease onset | ASO and ADB | ASO or ADB |
|---|---|---|
| Up to 1 year (n = 23) | 43% 1,2 | 65% 1,2 |
| Controls | 4.5% | 26% |
| 1-3 years (n = 42) | 33% 3,4 | 57% 3,4 |
| Controls | 9.5% | 30% |
| 3-10 years (n = 64) | 16% | 40% |
| Controls | 11% | 28% |
| ≥ 10 years (n = 65) | 6% | 29% |
| Controls | 3% | 25% |
1 OR = 16.1 (ASO and ADB); 5.3 (ASO or ADB), P < 0.01 versus age matched controls
2 OR = 11.7 (ASO and ADB); 4.5 (ASO or ADB), P < 0.01 versus patients > 10 years from onset
3 OR = 4.8 (ASO and ADB); 3.2 (ASO or ADB), P < 0.05 versus age matched controls
4 OR = 7.6 (ASO and ADB); 4.5 (ASO or ADB), P < 0.01 versus patients > 10 years from onset